Отдаленные результаты лечения пациентов с классической лимфомой Ходжкина в реальной клинической практике: опыт гематологического отделения Новосибирска

Abstract

Aim. To assess the long-term results of classical Hodgkin’s lymphoma (cHL) treatment in Novosibirsk in real-world clinical practice.
 Materials & Methods. The study enrolled 408 cHL patients treated and followed-up at the hematological unit of the Novosibirsk Municipal Clinical Hospital No. 2 from January 2008 to December 2021. The median age of patients was 33 years (range 26–44 years). Among them 223 (54.7 %) female and 185 (45.3 %) male patients. There were more patients with cHL stages III (n = 103; 25.2 %) and IV (n = 120; 29.4 %) than with stage II, which was identified in 185 (45.4 %) patients. ABVD regimen was administered to 132 (32.3 %) patients, 47 (11.5 %) patients received ABVD escalated to BEACOPP. BEACOPP therapy was performed in 229 (56.2 %) patients. Subsequent radiotherapy was assigned to 202 (49.5 %) patients. Second-line therapy was required by 89 (21.8 %) patients with relapsed and resistant cHL.
 Results. The 10-year overall survival (OS) was 81 %, and the 5-year OS was 91 %. Similar progression-free survival (PFS) rates were 86 % and 77 %, respectively. The 10-year PFS in patients with stage II was 87 %, while in patients with stages II (mediastinal bulky mass), III and IV, it was only 69 % (p = 0.002). The 10-year OS in patients with localized stages was 91 %, and in patients with generalized stages it was 79 % (p = 0.0006). The 10-year OS in patients less than 45 years of age was 88 %, and in patients more than 45 years of age it was 69 %. The 10-year PFS in patients less than 45 years of age was 84 %, and in the older age group it was 60 % (p = 0.001).
 Conclusion. The study results demonstrate high rates of long-term survival of cHL patients and are well comparable with the data of other study groups. Nevertheless, scientific research should be continued to develop optimal risk-adapted programs of cHL chemotherapy and to define further prospects for improving the treatment outcomes of this malignant tumor.